Market Applicability					
Market	**GA**	**KY**	**MD**	**NJ**	**NY**
Applicable	X	NA	X	X	X

Movantik (naloxegol)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Movantik (naloxegol)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Movantik (naloxegol) may be approved if the following criteria is met:

I. Individual is 18 years of age or older; **AND**
II. Individual has a diagnosis of non-cancer pain-related opioid-induced constipation (OIC); **AND**
III. The individual must have a previous trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of or insufficient response to two laxatives [e.g. polyethylene glycol (generic MiraLax), bisacodyl (Dulcolax), senna (Ex-lax)] (AGA 2013, 2019).

Requests for Movantik (naloxegol) may **not** be approved for the following:

I. Individual has a known, suspected, or at increased risk for gastrointestinal obstruction; **OR**
II. Concomitant use with strong CYP3A4 inhibitors (such as clarithromycin or ketoconazole).

Key References:

1. American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013 Jan;144(1):211-7. Available from: http://www.gastrojournal.org/article/S0016-5085(12)01545-4/pdf. Accessed on: January 14, 2021.
2. American Gastroenterological Association, Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019 Jan;156(1): 218-226. Available from: https://www.gastrojournal.org/article/S0016-5085(18)34782-6/pdf. Accessed on: January 14, 2021.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: http://www.clinicalpharmacology.com. Updated periodically.
4. Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Medical

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability					
Market	**GA**	**KY**	**MD**	**NJ**	**NY**
Applicable	X	NA	X	X	X

Management of Opioid-Induced Constipation. *Gastroenterology*. 2019 Jan;156(1):218-226. Available at: https://www.gastrojournal.org/article/S0016-5085(18)34782-6/fulltext Accessed on January 14, 2021.
5. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: January 14, 2021.
6. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
7. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.